Positive at-home HPV tests: next steps and 2027 follow-up coverage

Getting a positive result from an at-home HPV self-collection test can be stressful. But in most cases, a positive result is not a cancer diagnosis—it’s a screening signal that you need the next step in the screening pathway so clinicians can determine what follow-up testing is appropriate for you.

First, what a “positive” at-home HPV test usually means

HPV stands for human papillomavirus. Many at-home tests are designed to detect high-risk HPV (hrHPV), which is associated with a higher long-term risk of cervical cancer.

A positive hrHPV screening result does not mean you have cancer today. It means you may need additional screening or follow-up testing based on your age and your previous screening history, following your clinician’s recommended pathway.

What happens next (the screening pathway)

Follow-up steps can vary by the program and your individual screening history, but the goal is consistent: connect you quickly to the next recommended step so you don’t get “stuck” between receiving a result and getting care.

Contact the test program or your clinician promptly to understand what your positive result triggers.
Ask what test comes next and where it’s done (for example, an in-clinic test to complete screening, and/or another follow-up appointment).
Request a simple plan for timing and results: who schedules, how results are communicated, and when you should expect the next decision.

What changes in 2027 with HRSA’s updated screening guidance

On January 5, 2026, HRSA announced updates to the Women’s Preventive Services Guidelines that expand screening options and address insurance coverage for follow-up testing.

Age 30–65 (average risk): HRSA designates hrHPV testing as the preferred screening modality, while still allowing cervical cytology (Pap) as an option.
Self-collection option: HRSA includes self-collection as a screening option.
Age 21–29 (average risk): cervical cytology (Pap) is recommended.
Insurance coverage starting January 1, 2027: HRSA’s update includes new language requiring most insurance plans to cover additional testing needed to complete the screening process for malignancies, with coverage beginning January 1, 2027.

Coverage rules can still vary by plan and situation, so it’s smart to ask what portion of the follow-up test(s) you’ll owe before you schedule—especially during 2027’s transition period.

How FDA clearance fits in (what “cleared for at-home use” means)

FDA clearance is about the device’s intended use. For example, FDA’s De Novo database lists the Teal Wand as a device for home collection and transport of vaginal specimens by lay users for use with an approved HPV molecular assay.

FDA’s 510(k) decision summary for the Onclarity Self-Collection Kit describes the kit’s intended use for self-collection and transport of vaginal specimens for use with an FDA-approved HPV molecular assay with which the collection device has been validated.

Bottom line: a “positive at-home HPV test” should be understood as the screening result from a specific FDA-cleared kit and its matched laboratory assay—not as a standalone diagnosis.

Access reality check: why follow-up can be harder than the test

At-home self-collection can help people who struggle with transportation, scheduling, or privacy. But follow-up still matters—and research on mailed at-home HPV testing in real-world settings has highlighted that result communication and completing follow-up can be challenges for some people, including those relying on safety-net systems.

For people with low income and limited insurance coverage, the CDC notes that the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides access to timely screening and diagnostic services, including case management to help navigate care.

What you can do today if your at-home HPV test is positive

Don’t ignore the result. Treat it as a prompt to start the screening pathway with follow-up care.
Ask: what is the next step, and how soon? If you don’t get a clear answer, request one.
Ask about insurance coverage. If you have insurance, ask what your plan covers for the additional testing needed to complete screening—particularly given HRSA’s coverage update that begins January 1, 2027.
If you’re uninsured or underinsured: ask whether you can be connected through NBCCEDP or another local program that can help with screening and diagnostic services.

Quick takeaway

A positive at-home hrHPV result is a screening warning sign, not a cancer diagnosis. The most important next step is completing the screening pathway with prompt follow-up. Starting January 1, 2027, HRSA’s updated guidance is designed to reduce cost barriers for additional testing needed to complete screening for many people with insurance.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.